Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bojan Lalovic

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pharmacology|July 29, 2010
Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorderBojan Lalovic, Matt Hutmacher, Bill Frame, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2021
Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitorsTakashi Ueno, Yukiko Miyajima, Ishani Landry, et al.
Journal of Clinical Pharmacology|December 16, 2022
Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of InsomniaBojan Lalovic, Ishani Savant Landry, Margaret Moline, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 25, 2004
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomesBojan Lalovic, Brian Phillips, Linda L Risler, et al.
Anesthesiology Research and Practice|March 12, 2020
Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving HypothermiaRyan M McAdams, Daniel Pak, Bojan Lalovic, et al.
Journal of Clinical Pharmacology|July 16, 2020
Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia DisorderBojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
Clinical Pharmacology and Therapeutics|May 9, 2006
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolitesBojan Lalovic, Evan Kharasch, Christine Hoffer, et al.
Clinical Pharmacology in Drug Development|May 30, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy AdultsIshani Landry, Kenya Nakai, Jim Ferry, et al.
Clinical Pharmacokinetics|June 22, 2005
Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studiesEvan D Kharasch, Dale Whittington, Christine Hoffer, et al.
Clinical and Translational Science|February 26, 2025
Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaTheingi M Thway, Jagadeesh Aluri, Bojan Lalovic, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|July 29, 2010
Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorderBojan Lalovic, Matt Hutmacher, Bill Frame, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2021
Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitorsTakashi Ueno, Yukiko Miyajima, Ishani Landry, et al.
Journal of Clinical Pharmacology|December 16, 2022
Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of InsomniaBojan Lalovic, Ishani Savant Landry, Margaret Moline, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 25, 2004
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomesBojan Lalovic, Brian Phillips, Linda L Risler, et al.
Anesthesiology Research and Practice|March 12, 2020
Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving HypothermiaRyan M McAdams, Daniel Pak, Bojan Lalovic, et al.
Journal of Clinical Pharmacology|July 16, 2020
Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia DisorderBojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
Clinical Pharmacology and Therapeutics|May 9, 2006
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolitesBojan Lalovic, Evan Kharasch, Christine Hoffer, et al.
Clinical Pharmacology in Drug Development|May 30, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy AdultsIshani Landry, Kenya Nakai, Jim Ferry, et al.
Clinical Pharmacokinetics|June 22, 2005
Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studiesEvan D Kharasch, Dale Whittington, Christine Hoffer, et al.
Clinical and Translational Science|February 26, 2025
Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaTheingi M Thway, Jagadeesh Aluri, Bojan Lalovic, et al.
Pageof 2